Hints and tips:
Related Special Reports
...Before 2014, the investment company had no offices in developed countries but now its presence outside of Asia stretches from Paris and London to San Francisco and New York....
...Beijing has refused to import BioNTech/Pfizer and Moderna’s mRNA jabs for its domestic population, despite research showing they provide higher level and more long-lasting protection than the widely used...
Hard-driving founder Bhavish Aggarwal defends ‘intense’ company culture that created country’s biggest e-scooter maker
...Singapore GP Pte declined to comment. The Singapore Tourism Board did not immediately respond to requests for comment. Ong declined to comment....
...Partners have included Pfizer and Eli Lilly and it generated Rmb16.1bn ($2.2bn) in revenues last year from the 20 largest names and earned Rmb26bn — about two-thirds of its revenues — from the US, which...
...Europe was the chief laggard this past quarter, with regional deal activity down 63 per cent to $81.6bn, while the US saw a 47 per cent drop to $271.7bn and the Asia-Pacific region only declined by 24 per...
...The mRNA vaccine technology used by Moderna and BioNTech/Pfizer provides longer-lasting and higher levels of protection than the inactivated vaccine technology used by Chinese makers....
...Temasek said it would look to boost investments in India and south-east Asia....
...According to his LinkedIn page, he then spent two decades working for the China operations of major European and US multinational companies including BP, Pfizer Pharmaceuticals and General Motors....
Singaporean state investor ‘disappointed’ with the investment in the failed cryptocurrency exchange
...Crowding into the Hyatt Regency to meet the Chinese leader were Elon Musk of Tesla, Tim Cook of Apple and Albert Bourla of Pfizer, all keen on selling more electric cars, iPhones and pharmaceuticals in the...
...Public documents filed at Singapore’s corporate registry show Poxdo PTE Ltd was established in May 2020 and name two directors: Lee Ming Chung, a citizen of Singapore, and Nguyen Dac Manh of Ha Noi, Vietnam...
...Pfizer CEO Albert Bourla will join as part of his second visit to China in two months. Bourla told the FT earlier this month he still saw “very big” opportunity for Pfizer in the country....
...The agreement is a sign that AstraZeneca is investing in the mRNA technology that was used successfully for the first time in the Covid-19 jabs developed by BioNTech and Pfizer, and Moderna....
...Liu said Pfizer would not want to “damage their global price integrity” by reducing the price for China. “Pfizer cannot sacrifice the global market for China,” he added....
...The deal comes just a few weeks after Pfizer spent $43bn on SeaGen, a cancer treatments maker previously pursued by Merck....
...It is under pressure because its US patent for Xtandi, a popular prostate cancer drug whose sales are shared with Pfizer, is expiring in 2027....
...After seeing off a bid from Pfizer in 2014, AstraZeneca’s shares have risen more than 100 per cent in the past five years and its market capitalisation recently passed that of its US rival....
State-owned investment fund had written off $275mn holdings in Sam Bankman-Fried’s crypto group
Loss comes as bankrupt crypto exchange distances itself from founder Sam Bankman-Fried
...Chinese media have repeatedly criticised the BioNTech/Pfizer mRNA vaccine and questioned its safety....
...But the National Healthcare Security Administration, which negotiates drug prices for China’s national health insurance reimbursement scheme, balked at the “high price” quoted by Pfizer....
...China’s elites are stockpiling supplies of Paxlovid, Pfizer’s Covid-19 antiviral drug, and giving it away to curry favour with business associates as an unprecedented Covid wave leaves hospitals stripped...
...The birth and growth of these businesses have become the very symbol of the meteoric rise of south-east Asia’s tech ecosystem....
...Sales of the vaccine AstraZeneca developed with the University of Oxford, which have been outpaced by the mRNA jabs from BioNTech/Pfizer and Moderna, dropped by 98 per cent to $28mn....
International Edition